JAK inhibitors and tocilizumab elicit better response rates in VEXAS syndrome

New research at ACR Convergence 2023, the American College of Rheumatology's (ACR) annual meeting, found that JAK inhibitors (JAKi) and tocilizumab elicited better response rates in VEXAS syndrome compared to other targeted therapies.

Related Keywords

Paris ,France General ,France ,French ,Lily Ramsey ,Jerome Hadjadj ,American College Of Rheumatology ,American College ,Lassistance Publique ,Syndrome ,Flood ,Blood Vessels ,One ,Bone Marrow ,Chromosome ,Drugs ,Education ,Efficacy ,Nzyme ,Gene ,Inflammation ,Lungs ,Utation ,Mh ,Research ,Heumatology ,Skin ,Acuoles ,Sex Chromosome ,X Linked ,